Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.

13 Sep 2010

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Researchers are now investigating whether the human reovirus, when prescribed along with chemotherapy, will provide a desperately needed "one-two punch" against ovarian cancer.

13 Sep 2010

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.

13 Sep 2010

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

13 Sep 2010

Enlyton publishes cancer imaging study results of colorectal cancer

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.

13 Sep 2010

PCRI to host educational event on prostate cancer therapy

Dean Ornish MD, recognized for establishing the impact of diet on prostate cancer (and heart disease), along with over a dozen internationally recognized prostate cancer experts will meet with over 800 prostate cancer survivors and their significant others at the Los Angeles Marriott near LAX on September 11th and 12th to discuss the latest thinking on prostate cancer treatment.

13 Sep 2010

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal.

10 Sep 2010

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

10 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.

10 Sep 2010

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Diplomat Specialty Pharmacy announced today they have earned a position of 554 on Inc. Magazine's exclusive, annual ranking of the fastest-growing private companies in America.

10 Sep 2010

GE Healthcare to showcase molecular imaging portfolio at WMIC

Reinforcing its commitment to researchers and clinicians, GE Healthcare, a unit of General Electric Company is showcasing a comprehensive molecular imaging portfolio—encompassing tracer development, pre-clinical imaging and highly advanced imaging equipment— to provide insight into the origins of disease, at the World Molecular Imaging Congress (WMIC), Booth #212, September 8 through 11 in Kyoto, Japan.

10 Sep 2010

Meditrina licensor AstraZeneca granted US allowance of patent for endometriosis treatment

Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.

10 Sep 2010

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010

Halozyme Therapeutics announces public offering of 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced the pricing of its previously announced public offering of 8.3 million shares of its common stock at a price to the public of $7.50 per share.

10 Sep 2010

New melanoma drug in the pipeline from Plexxikon and Roche

Researchers from biotech company Plexxikon have found that their candidate drug for skin cancer melanomas can be administered more effectively in early stages of the disease.

9 Sep 2010

Roche announces Ambry Genetics as first US CSP for NimbleGen SeqCap EZ Exome workflow

Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research.

9 Sep 2010

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Anchor Therapeutics today announced that it has entered into a collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. with the goal of developing G protein coupled receptor (GPCR) targeted therapeutic compounds utilizing Anchor's proprietary pepducin technology.

9 Sep 2010

Oncology News and Research

Further Reading

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

Enlyton publishes cancer imaging study results of colorectal cancer

PCRI to host educational event on prostate cancer therapy

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

GE Healthcare to showcase molecular imaging portfolio at WMIC

Meditrina licensor AstraZeneca granted US allowance of patent for endometriosis treatment

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Noscira receives FDA approval for Tideglusib drug to treat PSP

Halozyme Therapeutics announces public offering of 8.3 million shares of common stock

New melanoma drug in the pipeline from Plexxikon and Roche

Roche announces Ambry Genetics as first US CSP for NimbleGen SeqCap EZ Exome workflow

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News